Enovis (NYSE:ENOV) Stock Price Up 4.6% – Here’s Why

Enovis Corporation (NYSE:ENOV)’s share price traded up 4.6% on Tuesday . The stock traded as high as $25.78 and last traded at $25.87. 60,484 shares were traded during trading, a decline of 95% from the average session volume of 1,100,257 shares. The stock had previously closed at $24.74.

Analysts Set New Price Targets

ENOV has been the topic of several analyst reports. Zacks Research upgraded shares of Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Canaccord Genuity Group decreased their price target on shares of Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a report on Monday. Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Wall Street Zen downgraded Enovis from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Evercore set a $32.00 target price on Enovis in a report on Monday, July 6th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Enovis presently has a consensus rating of “Moderate Buy” and an average target price of $41.29.

Enovis Trading Up 4.9%

The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84. The firm has a market capitalization of $1.50 billion, a P/E ratio of -1.34 and a beta of 1.34. The business has a 50 day moving average of $24.91 and a 200-day moving average of $24.05.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. The firm had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The business’s revenue was up 3.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts anticipate that Enovis Corporation will post 3.12 EPS for the current fiscal year.

Insider Activity at Enovis

In related news, insider Oliver Engert acquired 1,200 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the acquisition, the insider directly owned 51,840 shares in the company, valued at approximately $1,120,780.80. The trade was a 2.37% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have acquired 4,200 shares of company stock worth $92,084 in the last quarter. Company insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Enovis

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Arax Advisory Partners acquired a new stake in shares of Enovis in the 4th quarter valued at about $29,000. Allworth Financial LP bought a new stake in shares of Enovis in the second quarter valued at about $36,000. EverSource Wealth Advisors LLC boosted its position in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares during the period. Public Employees Retirement System of Ohio bought a new position in shares of Enovis during the second quarter worth about $48,000. Finally, Danske Bank A S bought a new position in shares of Enovis during the third quarter worth about $64,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.